Literature DB >> 30031728

Increased Levels of Oxidative Damage in Liver Metastases Compared with Corresponding Primary Colorectal Tumors: Association with Molecular Subtype and Prior Treatment.

Lizet M van der Waals1, Jennifer M J Jongen1, Sjoerd G Elias2, Kateryna Veremiyenko1, Kari Trumpi1, Anne Trinh3, Jamila Laoukili1, Inge Ubink1, Susanne J Schenning-van Schelven1, Paul J van Diest4, Inne H M Borel Rinkes1, Onno Kranenburg5.   

Abstract

High levels of oxidative stress in disseminated colorectal cancer tumor cells may form a therapeutically exploitable vulnerability. However, it is unclear whether oxidative stress and damage persist in metastases. Therefore, we analyzed markers of oxidative damage in primary colorectal tumors and their corresponding liver metastases. Markers of generic and oxidative DNA damage [phosphorylated histone H2AX (γH2AX) and 8-hydroxy-2'-deoxyguanosine (8-OHdG)] were significantly higher in liver metastases compared with their corresponding primary tumors. Chemotherapy and/or radiotherapy before tumor resection was associated with increased persistent oxidative DNA damage, and this effect was more pronounced in metastases. Immunohistochemistry-based molecular classification into epithelial- and mesenchymal-like molecular subtypes revealed that untreated mesenchymal-like tumors contained lower levels of oxidative DNA damage compared with epithelial-like tumors. Treated mesenchymal-like tumors, but not epithelial-like tumors, showed significantly higher levels of γH2AX and 8-OHdG. Mesenchymal-like tumors expressed significantly lower levels of phosphorylated nuclear factor erythroid 2-related factor 2, a master regulator of the antioxidant response, and nuclear factor erythroid 2-related factor 2-controlled genes. Of interest, a positive 8-OHdG status identified a subgroup of mesenchymal-like metastases with a poor overall survival. An increased capacity to tolerate therapy-induced oxidative damage in mesenchymal-like colorectal cancer may explain, at least in part, the poor responsiveness of these tumors to chemotherapy, which could contribute to the poor survival of this patient subgroup.
Copyright © 2018 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 30031728     DOI: 10.1016/j.ajpath.2018.06.008

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  5 in total

1.  Fibroblast activation protein identifies Consensus Molecular Subtype 4 in colorectal cancer and allows its detection by 68Ga-FAPI-PET imaging.

Authors:  Esther Strating; Emma Wassenaar; Mathijs Verhagen; Paulien Rauwerdink; Susanne van Schelven; Ignace de Hingh; Inne Borel Rinkes; Djamila Boerma; Arjen Witkamp; Miangela Lacle; Riccardo Fodde; Richard Volckmann; Jan Koster; Kris Stedingk; Frederik Giesel; Remmert de Roos; Alex Poot; Guus Bol; Marnix Lam; Sjoerd Elias; Onno Kranenburg
Journal:  Br J Cancer       Date:  2022-03-16       Impact factor: 9.075

2.  Differential anti-tumour effects of MTH1 inhibitors in patient-derived 3D colorectal cancer cultures.

Authors:  Lizet M van der Waals; Jamila Laoukili; Jennifer M J Jongen; Danielle A Raats; Inne H M Borel Rinkes; Onno Kranenburg
Journal:  Sci Rep       Date:  2019-01-28       Impact factor: 4.379

3.  Circadian and chemotherapy-related changes in urinary modified nucleosides excretion in patients with metastatic colorectal cancer.

Authors:  S Dulong; Q Huang; P F Innominato; A Karaboue; M Bouchahda; A Pruvost; F Théodoro; L A Agrofoglio; R Adam; B Finkenstädt; F Lévi
Journal:  Sci Rep       Date:  2021-12-14       Impact factor: 4.379

4.  ALDH1A1 expression is associated with poor differentiation, 'right-sidedness' and poor survival in human colorectal cancer.

Authors:  Lizet M van der Waals; Inne H M Borel Rinkes; Onno Kranenburg
Journal:  PLoS One       Date:  2018-10-11       Impact factor: 3.240

5.  Clinical Value of Consensus Molecular Subtypes in Colorectal Cancer: A Systematic Review and Meta-Analysis.

Authors:  Sanne Ten Hoorn; Tim R de Back; Dirkje W Sommeijer; Louis Vermeulen
Journal:  J Natl Cancer Inst       Date:  2022-04-11       Impact factor: 13.506

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.